PERTH, Australia – Dimerix Ltd. has begun recruiting patients for two separate phase II trials of its kidney disease candidate, DMX-200, in diabetic kidney disease and in orphan disease focal ...
The patent titled N-cyanopyrrolidines with activity as USP30 inhibitors has been issued to Dimerix (ASX:DXB) under patent number 438406 by the Mexican Institute of Industrial Property (IMPI). It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results